Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica

Inclusion Criteria:

• 1. Age 18-60 and gender unlimited;
• 2. NMOSD diagnosed based on the 2015 NMOSD International Consensus DiagnosticCriteria;
• 3. Diagnostic criteria for AQP4-IgG positive NMOSD Diagnostic criteria for AQP4-IgGpositive NMOSD

1. At least 1 core clinical feature
2. Using reliable methods to detect positive AQP4-IgG (CBA method)
3. Exclude other diagnoses. Core clinical features
4. ＯＮ
5. Acute myelitis
6. Posterior region syndrome, unexplained paroxysmal hiccup, nausea, and vomiting
7. Other brainstem syndromes
8. Symptomatic episodic sleeping sickness, diencephalic syndrome, brain MRI withNMOSD characteristic diencephalic lesions
9. Cerebral syndrome with NMOSD characteristic brain lesions

• 4. Corticosteroids combined with immunosuppressants (azathioprine or mycophenolatemofetil or rituximab) still relapse after treatment；
• 5. At least 2 relapses within the past 12 months or at least 3 relapses within thepast 24 months, and at least 1 recurrence within the 12 months prior to screening；
• 6. The estimated survival time is more than 12 weeks;
• 7. Women of childbearing age who have negative urine pregnancy test before medicationadministration and agree to take effective contraceptive measures during the trialperiod until the last follow-up

Exclusion Criteria:

• 1. Epilepsy history or other central nervous system disease;
• 2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severearrhythm ia in the past;
• 3. Pregnant (or lactating) women;
• 4. Patients with severe active infections;
• 5. Active infection of hepatitis B virus or hepatitis C virus;
• 6. Systemic steroids have used in the 4 weeks before participating in the treatment (except recently or currently using inhaled steroids);
• 7. Those who have used any gene therapy products before;
• 8. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulationsignal;
• 9. Serum creatinine > 2.5mg/dl or ALT / AST > 3 times ULN or bilirubin > 2.0mg/dl;
• 10. Those who suffer from other uncontrolled diseases are not suitable to join thestudy;
• 11. HIV infection;
• 12. Any situation that the researchers believe may increase the risk of patients orinterfere with the test results.